Prostate Specific Antigen News and Research

RSS

PSA test is now all but useless for predicting prostate cancer risk

The PSA test, commonly used as a screening tool for detecting prostate cancer, is now all but useless for predicting prostate cancer risk, according to Stanford University School of Medicine researchers.

10 Sep 2004

Study reveals what may be the earliest step in the development of prostate cancer

The finding could open the door to new tests that predict whether the cancer will become aggressive and the development of treatments to prevent the condition from progressing.

2 Sep 2004

Combination therapies improve prostate cancer survival rates

The addition of six months of androgen suppression therapy (AST) to radiation therapy improves survival of patients with clinically localized prostate cancer, according to a study in the current issue of the Journal of the American Medical Association.

18 Aug 2004

Combination of hormonal therapy, radioactive seed implant and external beam radiation therapy increases chance of cancer cure

High-risk prostate cancer patients who undergo a combination of hormonal therapy, radioactive seed implant (also called brachytherapy) and external beam radiation therapy are shown to have an increased chance of cancer cure

29 Jul 2004

Stat5 protein is particularly plentiful in high histological grade human prostate cancer

Prostate cancer is much more likely to be aggressive if a key protein called Stat5 is found activated and in abundance in the cancer cells, report researchers from Georgetown University's Lombardi Comprehensive Cancer Center.

15 Jul 2004

Joint initiative to tackle cancer, diabetes, heart disease and stroke

Three of the nation’s leading not-for-profit health agencies today announced a joint initiative to empower Americans to help lower their risk of cancer, diabetes, heart disease and stroke by following a single set of recommendations.

16 Jun 2004

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

Johns Hopkins Kimmel Cancer Center clinicians were among those at leading institutions that have completed a three-year international study showing that docetaxel, a drug made from yew tree needles, decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy.

11 Jun 2004

Prostate cancer immunotherapy vaccine hits clinical trials

Scientists at the Austrlia's, Queensland Institute of Medical Research (QIMR) are currently trialing an experimental "immunotherapy" treatment for men with advanced prostate cancer.

10 Jun 2004

Non-aspirin pain drugs may help men with recurrent prostate cancer

Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

10 Jun 2004

Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer

Men who take even small amounts of common cholesterol-lowering drugs such as Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer, according to a new study by Oregon Health & Science University Cancer Institute researchers.

9 Jun 2004

Current test for prostate cancer is inadequate

Britain’s top cancer scientists claim that men’s health is at risk because the current test for prostate cancer is inadequate. The warning comes as The Institute of Cancer Research launches the 7th Everyman Male Cancer Awareness Month to alert men to the risk of prostate and testicular cancer.

27 May 2004

Men with low prostate specific antigen levels on screening tests can still have prostate cancer

Men with low PSA (prostate specific antigen) levels on screening tests can still have prostate cancer, according to a study* released today by scientists from the National Cancer Institute (NCI).

27 May 2004

Overweight post prostate cancer surgery patients have greater chance of cancer recurrence

After prostate cancer surgery, obese men are more likely than men with normal weight to have high levels of prostate specific antigen (PSA), a marker for cancer recurrence, according to a study led by Johns Hopkins researchers.

9 May 2004

New British survey illustrates the difficulties in targeting health services at men

A new survey by the Prostate Research Campaign UK illustrates the difficulties in targeting health services at men. More than 80% of the men surveyed claimed to book their GP appointments themselves - but 39% of their wives or partners said that in fact it was they who did it.

29 Apr 2004